Ocuphire Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Disease

Ocuphire Selected to Present at Multiple Ophthalmic Conferences in July

2021 ASCRS Annual Meeting

Jul 25 – Jul 26, 2021

Demy-Colton Virtual Salon Series

Jul 28, 2021 • 11:00am - 12:15pm EDT